You are here

Daiichi-Sankyo

2020

Ken Keller

President and CEO

Ken Keller is President and CEO of Daiichi Sankyo, Inc. He also leads the U.S. Business and serves as a member of Daiichi Sankyo’s Global Management Committee. Mr. Keller joined Daiichi Sankyo Inc. in 2014.

Through his work with Daiichi Sankyo, and prior to that with Amgen Inc., Mr. Keller has more than 30 years of experience in the pharmaceutical industry. He has led multi-billion dollar businesses in the U.S. and Europe.

Through leadership roles in multiple markets, across cultures and within different healthcare systems, Mr. Keller has successfully launched numerous biologic products in therapeutic areas ranging from oncology to bone health to nephrology to inflammatory diseases, transformed businesses, and delivered sustainable revenue and profit growth

Since joining Daiichi Sankyo, Inc., Mr. Keller has shifted the structure of the U.S. business to focus on launching multiple oncology therapeutics in the coming years. He is known for his inclusive leadership approach and his passion for bringing innovative drugs to patients in need.

Mr. Keller is a member of the PhRMA Board of Directors and was previously a board member of the Association of the British Pharmaceutical Industry. He holds a Bachelor of Science degree in Business from Saint John's University and a Master of Business Administration degree from Loyola Marymount University.

Daiichi-Sankyo

Daiichi Sankyo is a global pharmaceutical company with corporate origins in Japan. It provides innovative products and services in more than 20 countries around the world. With more than 100 years of scientific expertise, the company draws upon a rich legacy of innovation and a robust pipeline of promising new medicines to help patients.